Stoke Therapeutics' stock surged after positive clinical trial data for STK-001 in treating Dravet syndrome in children.

Stoke Therapeutics' (STOK) stock surged over 70% after the company announced positive clinical trial data for its drug, STK-001, in treating Dravet syndrome in children aged 2 to 18. The drug showed clinically meaningful effects, including substantial and durable reductions in seizure frequency and improvements in cognition and behavior. Stoke Therapeutics plans to discuss a registrational study with regulatory agencies.